1. Home
  2. LEGN vs JHG Comparison

LEGN vs JHG Comparison

Compare LEGN & JHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • JHG
  • Stock Information
  • Founded
  • LEGN 2014
  • JHG 1934
  • Country
  • LEGN United States
  • JHG United Kingdom
  • Employees
  • LEGN N/A
  • JHG N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • JHG Investment Managers
  • Sector
  • LEGN Health Care
  • JHG Finance
  • Exchange
  • LEGN Nasdaq
  • JHG Nasdaq
  • Market Cap
  • LEGN 7.0B
  • JHG 5.8B
  • IPO Year
  • LEGN 2020
  • JHG N/A
  • Fundamental
  • Price
  • LEGN $33.65
  • JHG $35.78
  • Analyst Decision
  • LEGN Strong Buy
  • JHG Hold
  • Analyst Count
  • LEGN 13
  • JHG 11
  • Target Price
  • LEGN $79.17
  • JHG $43.18
  • AVG Volume (30 Days)
  • LEGN 1.1M
  • JHG 1.6M
  • Earning Date
  • LEGN 03-11-2025
  • JHG 05-01-2025
  • Dividend Yield
  • LEGN N/A
  • JHG 4.34%
  • EPS Growth
  • LEGN N/A
  • JHG 8.02
  • EPS
  • LEGN N/A
  • JHG 2.56
  • Revenue
  • LEGN $627,241,000.00
  • JHG $2,473,200,000.00
  • Revenue This Year
  • LEGN $66.60
  • JHG $6.78
  • Revenue Next Year
  • LEGN $49.28
  • JHG $8.86
  • P/E Ratio
  • LEGN N/A
  • JHG $14.05
  • Revenue Growth
  • LEGN 119.97
  • JHG 17.67
  • 52 Week Low
  • LEGN $30.17
  • JHG $30.35
  • 52 Week High
  • LEGN $60.87
  • JHG $46.68
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 44.07
  • JHG 33.52
  • Support Level
  • LEGN $34.00
  • JHG $36.82
  • Resistance Level
  • LEGN $36.20
  • JHG $38.18
  • Average True Range (ATR)
  • LEGN 1.52
  • JHG 0.96
  • MACD
  • LEGN -0.25
  • JHG 0.08
  • Stochastic Oscillator
  • LEGN 25.18
  • JHG 9.55

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About JHG Janus Henderson Group plc

Janus Henderson Group provides investment management services to retail intermediary (56% of managed assets), self-directed (23%) and institutional (21%) clients. At the end of September 2024, active equities (63%), fixed-income (21%), multi-asset (14%) and alternative (2%) investment platforms constituted the company's $382.3 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (61%), with customers from Europe, the Middle East, Africa, and Latin America (29%) and the Asia-Pacific region (10%) accounting for the remainder.

Share on Social Networks: